To Assess the Safety of Avanafil in Healthy and Hepatically Impaired Male Subjects.
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the single dose pharmacokinetics of avanafil in
subjects with hepatic impairment and in healthy control subjects.